{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:59:08Z","timestamp":1771257548879,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40261-023-01315-1","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T13:02:13Z","timestamp":1698930133000},"page":"873-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial"],"prefix":"10.1007","volume":"43","author":[{"given":"Xue-Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamilla Buchberg","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janka","family":"Ryding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-3012","authenticated-orcid":false,"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jette Buch","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-1681","authenticated-orcid":false,"given":"Frank","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"10283","key":"1315_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485\u201395.","journal-title":"Lancet"},{"issue":"3","key":"1315_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354.","journal-title":"Cephalalgia"},{"issue":"13","key":"1315_CR3","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2020;94(13):e1365\u201377.","journal-title":"Neurology"},{"issue":"3","key":"1315_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clinthera.2022.01.006","volume":"44","author":"V Martin","year":"2022","unstructured":"Martin V, Nagy AJ, Janelidze M, Giorgadze G, Hirman J, Cady R, et al. Impact of baseline characteristics on the efficacy and safety of eptinezumab in patients with migraine: subgroup analyses of PROMISE-1 and PROMISE-2. Clin Ther. 2022;44(3):389\u2013402.","journal-title":"Clin Ther"},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/ene.15670","volume":"30","author":"PJ Goadsby","year":"2023","unstructured":"Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, et al. Eptinezimab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol. 2023;30:1089\u201398.","journal-title":"Eur J Neurol"},{"issue":"23","key":"1315_CR6","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325(23):2348\u201356.","journal-title":"JAMA"},{"issue":"2","key":"1315_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M, Rubets I, Pederson S, Trinh M, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;8(2): e00567.","journal-title":"Pharmacol Res Perspect"},{"key":"1315_CR8","first-page":"1","volume":"5","author":"B Baker","year":"2022","unstructured":"Baker B, Shen V, Cady R, Ettrup A, Larsen F. Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and\/ or patients with migraine: early development studies. Cephalalgia Rep. 2022;5:1\u201311.","journal-title":"Cephalalgia Rep."},{"issue":"2","key":"1315_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1517\/17425255.2015.990438","volume":"11","author":"S Matsushima","year":"2015","unstructured":"Matsushima S, Huang Y, Suzuki H, Nishino J, Lloyd P. Ethnic sensitivity assessment\u2014pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs. Expert Opin Drug Metab Toxicol. 2015;11(2):179\u201391.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"1315_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1177\/0091270011411192","volume":"52","author":"H Zhou","year":"2011","unstructured":"Zhou H, Tsukamoto Y, Davis H. Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies? J Clin Pharmacol. 2011;52(8):1273\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1315_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/jcph.231","volume":"54","author":"K Chiba","year":"2014","unstructured":"Chiba K, Yoshitsugu H, Kyosaka Y, Iida S, Yoneyama K, Tanigawa T, et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol. 2014;54(5):483\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1315_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Ternant D. Pharmacokinetic Variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59(7):857\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"1315_CR13","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. 2022. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 24 Mar 2023."},{"key":"1315_CR14","unstructured":"ICH. ICH Harmonised Guideline E6(R2): integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice. 2016. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 24 Mar 2023."},{"key":"1315_CR15","unstructured":"U.S. Department of Health and Human Services. Bioanalytical method validation: guidance for industry. 2018. p. 1\u201344. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 24 Mar 2023."},{"key":"1315_CR16","unstructured":"Chinese Pharmacopoeia Commission. 9012\u2014Guideline for Validation of Quantitative Analytical Methods for Biological Samples. Chinese Pharmacopoeia; 2020."},{"issue":"1","key":"1315_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/pr800545q","volume":"8","author":"MK Tuck","year":"2009","unstructured":"Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113\u20137.","journal-title":"J Proteome Res"},{"key":"1315_CR18","unstructured":"U.S. Department of Health and Human Services. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection. 2019. https:\/\/www.fda.gov\/media\/119788\/download. Accessed 24 Mar 2023."},{"key":"1315_CR19","unstructured":"NMPA. Technical Guidelines for Drug Immunogenicity Research. 2021."},{"issue":"7","key":"1315_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135.","journal-title":"Pharm Res"},{"issue":"7","key":"1315_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40261-022-01171-5","volume":"42","author":"Q Shen","year":"2022","unstructured":"Shen Q, Jin Y, Di X, Hu C, Liu R, Wang Y, et al. Pharmacokinetics and safety of erenumab after a single subcutaneous injection dose in healthy Chinese subjects. Clin Drug Investig. 2022;42(7):623\u201330.","journal-title":"Clin Drug Investig"},{"key":"1315_CR22","unstructured":"VYEPTI [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761119s002lbl.pdf. Accessed 24 Mar 2023."},{"key":"1315_CR23","unstructured":"EMGALITY [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761063s000lbl.pdf. Accessed 24 Mar 2023."},{"key":"1315_CR24","unstructured":"AJOVY [package insert]. North Wales, PA: Teva Pharmaceuticals USA; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761089s002lbl.pdf. Accessed 24 Mar 2023."},{"key":"1315_CR25","unstructured":"AIMOVIG [package insert]. Thousand Oaks, CA: Amgen Inc.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf. Accessed 24 Mar 2023."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01315-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:21:15Z","timestamp":1699442475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01315-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01315-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"4 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial and publication support were funded by H. Lundbeck A\/S, Copenhagen, Denmark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"XNL and HRX have no conflicts of interest to declare. EC, KBP, JR, AE, JB\u00d8, and FL are full-time employees at Lundbeck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in compliance with Good Clinical Practice and in accordance with the ethical principles described in the Declaration of Helsinki. All study procedures were approved by the Medical Ethics Committees of Fudan University, Zhongshan Hospital (approval number: 2020-110; approval date: 19 October 2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study prior to trial enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In accordance with The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) Principles for Responsible Clinical Trial Data Sharing guidelines, H. Lundbeck A\/S is committed to responsible sharing of clinical trial data in a manner that is consistent with safeguarding the privacy of patients, respecting the integrity of national regulatory systems and protecting the intellectual property of the sponsor. The protection of intellectual property ensures continued research and innovation in the pharmaceutical industry. Deidentified data are available to those whose request has been reviewed and approved through an application submitted to .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to the conception of this manuscript, including design of the trial, analysis, and interpretation of data. All authors drafted the manuscript or revised it critically for important intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}